Jul 2026· Journal of Biological Chemistry· Vol 302, pp. 113374· 0 citations· 38 references
Medicine
TL;DR
Findings provide compelling evidence that CD147 enhances autophagic clearance of pro-fibrotic effectors and suppresses fibrotic progression through glycosylation-dependent mechanisms.
Abstract
Idiopathic pulmonary fibrosis (IPF) is a progressive and invariably fatal interstitial lung disease driven by persistent alveolar epithelial injury, which triggers aberrant fibroblast activation and pathological myofibroblast differentiation. In this study, we identify CD147—a heavily glycosylated transmembrane protein of the immunoglobulin superfamily—as a novel glycosylation-dependent regulator of pulmonary fibrosis operating through dual mechanistic pathways. CD147 expression was markedly downregulated in fibrotic lung tissues and predominantly localized to pulmonary fibroblasts. CD147 depletion significantly enhances fibroblast activation, proliferation, and extracellular matrix (ECM) production. Mechanistically, CD147 promotes autophagosome formation and facilitates p62 degradation, indicating its function in augmenting autophagic clearance of pro-fibrotic effectors. Notably, the anti-fibrotic activity of CD147 is strictly contingent upon its N-linked glycosylation status, the fully glycosylated CD147 robustly suppresses fibroblast-to-myofibroblast transformation and ECM deposition, while non-glycosylated isoforms are entirely devoid of this regulatory capacity. These findings provide compelling evidence that CD147 enhances autophagic clearance of pro-fibrotic effectors and suppresses fibrotic progression through glycosylation-dependent mechanisms.
Fibrosis is a pathological process primarily characterized by excessive deposition of extracellular matrix (ECM), which leads to disruption of tissue architecture and progressive loss of organ function, serving as a key pathological basis for various chronic diseases. Recent studies have revealed that, in addition to c...
Hua Guo, Xiao-Xiao Tang· Frontiers in Immunology· 0 citations
Pulmonary fibrosis (PF) is a progressive and fatal interstitial lung disease with limited therapeutic options. PDZ-binding kinase (PBK), also known as T-cell-originated protein kinase activated by lymphokines (TOPK), is implicated in cancer progression and inflammation, yet its role in fibrosis remains unexplored. This...
T. Ruan, Yu Zhen, Bei-Lei Wang et al.· International Journal of Bio...· 0 citations
A CD28-JAK1/STAT6-Th2-monocyte-derived alveolar macrophage pathway is defined as a mechanistic driver of pulmonary fibrosis and nominate CD28 and STAT6 as actionable immunologic targets that could complement existing antifibrotic therapies.
Yudai Miyashita, T. Kaiho, Raul Piseaux Aillon et al.· American Journal of Respirat...· 0 citations
The mechanisms underlying disease progression in idiopathic pulmonary fibrosis (IPF) and other interstitial lung diseases remain unclear. Increased extracellular matrix stiffness is a hallmark of fibrotic lung diseases, while monocyte-derived macrophages promote fibrosis progression. However, there is limited understan...
Chao He, C. Coarfa, Neftali Garcia et al.· bioRxiv· 0 citations
It is suggested that MAGI2 acts as a negative regulator of myofibroblast differentiation by stabilizing PTEN, whereas PREX2 is aberrantly expressed in the fibrotic milieu, negatively modulating MAGI2, thereby accelerating pulmonary fibrosis.
Yozo Sato, K. Kamio, Yasuhiro Terasaki et al.· American Journal of Physiolo...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.